The light at the end of the tunnel for chemical-specific biomarkers: Daylight or headlight?

Carcinogenesis

Volumn 20, Issue 1, 1999, Pages 1-11

  Groopman, John D ^a   Kensler, Thomas W ^a  

^a The Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; BIOCHEMICAL MARKER; CARCINOGEN; ENVIRONMENTAL CHEMICAL; OLTIPRAZ;

ANIMAL EXPERIMENT; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COHORT ANALYSIS; ENVIRONMENTAL EXPOSURE; GENETICS; HUMAN; LONGITUDINAL STUDY; MOLECULAR BIOLOGY; MONITORING; PHASE 2 CLINICAL TRIAL; POPULATION RISK; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; TOXICITY;

AFLATOXINS; ANIMALS; ANTICARCINOGENIC AGENTS; BIOLOGICAL MARKERS; BIOTRANSFORMATION; CARCINOGENS, ENVIRONMENTAL; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHINA; CLINICAL TRIALS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; DNA ADDUCTS; DNA DAMAGE; ENVIRONMENTAL EXPOSURE; FOOD CONTAMINATION; FORECASTING; GENE EXPRESSION REGULATION; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; LONGITUDINAL STUDIES; NEOPLASMS; PHILIPPINES; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 0032919238     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/20.1.1     Document Type: Review

References (58)

1. Anonymous (1987) Biological markers in environmental health research. Environ. Health Perspect., 74, 3-9.
2. Wogan, G.N. (1992) Molecular epidemiology in cancer risk assessment and prevention: recent progress and avenues for future research. Environ. Health Perspect., 98, 167-178.
3. Links, J.M., Kensler, T.W. and Groopman, J.D. (1995) Biomarkers and mechanistic approaches in environmental epidemiology. Annu. Rev. Public Health, 16, 83-103.
4. Hulka, B.S. (1991) Epidemiological studies using biological markers: issues for epidemiologists. Cancer Epidemiol. Biomarkers Prev., 1, 13-20.
5. Busby, W.F. and Wogan, G.N. (1984) Aflatoxins. In Searle, C.E. (ed.) Chemical Carcinogens. American Chemical Society, Washington, DC, pp. 945-1136.
6. Eaton, D.L. and Groopman, J.D. (eds) (1994) The Toxicology of Aflatoxins: Human Health, Veterinary and Agricultural Significance. Academic Press, San Diego, CA.
7. Ellis, W.O., Smith, J.P., Simpson, B.K. and Oldham, J.H. (1991) Aflatoxin in food: occurrence, biosynthesis, effects on organisms, detection and methods of control. Crit. Rev. Food Sci. Nutr., 30, 403-439.
8. Groopman, J.D., Scholl, P. and Wang, J.S. (1996) Epidemiology of human aflatoxin exposures and their relationship to liver cancer. Prog. Clin. Biol. Res., 395, 211-222.
9. 1 in vitro. Proc. Natl Acad. Sci. USA, 74, 1870-1874.
10. 1 in vivo in rats. Carcinogenesis, 8, 819-824.
11. 1-treated rats. Cancer Res., 41, 650-654.
12. 7-guanine and serum aflatoxin-albumin adducts predicts chemoprotection by 1,2-dithiole-3-thione in rats. Carcinogenesis, 13, 101-106.
13. Groopman, J.D., Trudel, L.J., Donahue, P.R., Marshak-Rothstein, A. and Wogan, G.N. (1984) High-affinity monoclonal antibodies for aflatoxins and their application to solid-phase immunoassays. Proc. Natl Acad. Sci. USA, 81, 7728-7731.
14. Groopman, J.D., Donahue, P.R., Zhu, J., Chen, J. and Wogan, G.N. (1985) Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography. Proc. Natl Acad. Sci. USA, 82, 6492-6496.
15. 7-guanine and other aflatoxin metabolites by multiple monoclonal antibody affinity chromatography and immunoaffinity/high performance liquid chromatography. Cancer Res., 52, 267-274.
16. 7-guanine formation and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. Cancer Res., 46, 3924-3931.
17. Egner, P.A., Gange, S.J., Dolan, P.M., Groopman, J.D., Muñoz, A. and Kensler, T.W. (1995) Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. Carcinogenesis, 16, 1769-1773.
18. 1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiothione. Carcinogenesis, 6, 759-763.
19. 1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res., 51, 5501-5506.
20. Bolton, M.G., Muñoz, A., Jacobson, L.P., Groopman, J.D., Maxuitenko, Y.Y., Roebuck, B.D. and Kensler, T.W. (1993) Transient intervention with olitpraz protects against aflatoxin-induced hepatic tumorigenesis. Cancer Res., 53, 3499-3504.
21. Kensler, T.W., Gange, S.J., Egner, P.A., Dolan, P.M., Munoz, A., Groopman, J.D., Rogers, A.E. and Roebuck, B.D. (1997) Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer. Cancer Epidemiol. Biomarkers Prev., 6, 603-610.
22. 1 in human urine. Nature, 227, 403-404.
23. 1 in human urine collected in Murang' a district, Kenya. Carcinogenesis, 4, 1193-1195.
24. 1-guanine adduct and hepatitis B virus infection in areas with different liver cancer incidence in Kenya. Cancer Res., 47, 3430-3433.
25. Groopman, J.D., Jiaqi, Z., Donahue, P.R., Pikul, A., Lisheng, Z., Jun-shi, C. and Wogan, G.N. (1992) Molecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi Autonomous Region, People's Republic of China. Cancer Res., 52, 45-52.
26. 7-guanine in human urine obtained in The Gambia, West Africa. Cancer Epidemiol. Biomarkers Prev., 1, 221-227.
27. 1. Carcinogenesis, 9, 1323-1325.
28. Wild, C.P., Hudson, G.J., Sabbioni, G., Chapot, B., Hall, A.J., Wogan, G.N., Whittle, H., Montesano, R. and Groopman, J.D. (1992) Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in The Gambia, West Africa. Cancer Epidemiol. Biomarkers Prev., 1, 229-234.
29. Harris, C.C. (1993) p53: at the crossroads of molecular carcinogenesis and risk assessment. Science, 262, 1980-1981.
30. Greenblatt, M.S., Bennett, W.P., Hollstein, M. and Harris, C.C. (1994) Perspectives in cancer research. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878.
31. Hsu, I.C., Metcalf, R.A., Sun, T., Welsh, J.A., Wang, N.J. and Harris, C.C. (1991 Mutational hotspot in the p53 gene in human hepatocellular carcinomas (letter). Nature, 350, 427-428.
32. Bressac, B., Kew, M., Wands, J. and Ozturk, M. (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature, 350, 429-431.
33. Wild, C.P., Fortuin, M., Donato, F., Whittle, H.C., Hall, A.J., Wolf, C.R. and Montesano, R. (1993) Aflatoxin, liver enzymes and hepatitis B virus infection in Gambian children. Cancer Epidemiol. Biomarkers Prev., 2, 555-561.
34. Fujimoto, Y., Hampton, L.L., Wirth, P.J., Wang, N.J., Xie, J.P. and Thorgeirsson, S.S. (1994) Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res., 54, 281-285.
35. Aguilar, F., Harris, C.C., Sun, T., Hollstein, M. and Cerutti, P. (1994) Geographic variation of p53 mutational profile in nonmalignant human liver. Science, 264, 1317-1319.
36. Ozturk, M. (1991) p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet, 338, 1356-1359.
37. 1. Proc. Natl Acad. Sci. USA, 80, 2695-2698.
38. Puisieux, A., Lim, S., Groopman, J. and Ozturk, M. (1991) Advances in brief. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res., 51, 6185-6189.
39. 1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl Acad. Sci. USA, 90, 8586-8590.
40. Wang, J.-S., Qian, G.-S., Zarba, A. et al. (1996) Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin, Qidong County, People's Republic of China. Cancer Epidemiol. Biomarkers Prev., 5, 253-261.
41. Kensler, T.W., Gange, S.J., Egner, P.A., Dolan, P.M., Munoz, A., Groopman, J.D., Rogers, A.E. and Roebuck, B.D. (1997) Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer. Cancer Epidemiol. Biomarkers Prev., 6, 603-610.
42. Bulatao-Jayme, J., Almero, E.M., Castro, M.A.C.A., Jardeleza, M.A.T.R. and Salamat, L.A. (1982) A case-control dietary study of primary liver cancer risk from aflatoxin exposure. Int. J. Epidemiol., 11, 112-119.
43. Van Rensburg, S.J., Cook-Mozaffari, P., Van Schalkwyk, D.J., Van Der Watt, J.J., Vincent, T.J. and Purchase, I.F. (1985) Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br. J. Cancer, 51, 713-726.
44. Peers, F.G. (1977) Dietary aflatoxins and human primary liver cancer. Ann. Nutr. Aliment., 31, 1005-1018.
45. Yeh, F.-S. and Shen, K.-N. (1986) Epidemiology and early diagnosis of primary liver cancer in China. Adv. Cancer Res., 47, 297-329.
46. Yeh, F.-S., Yu, M.C., Mo, C.-C., Luo, S., Tong, M.J. and Henderson, B.E. (1989) Hepatitis B virus, aflatoxins and hepatocellular carcinoma in southern Guangxi, China. Cancer Res., 49, 2506-2509.
47. Lunn, R.M., Zhang, Y.-J., Wang, L.-Y., Chen, C.-J., Lee, P.-H., Lee, C.-S., Tsai, W.-Y. and Santella, R.M. (1997) p53 mutations, chronic hepatitis B virus infection and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res., 57, 3471-3477.
48. 1. Proc. Natl Acad. Sci. USA, 92, 2384-2387.
49. Ross, R.K., Yuan, J.-M., Yu, M.C., Wogan, G.N., Qian, G.-S., Tu, J.-T., Groopman, J.D., Gao, Y.-T. and Henderson, B.E. (1992) Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, 339, 943-946.
50. Qian, G.-S., Ross, R.K., Yu, M.C., Yuan, J.-M., Gao, Y.-T., Henderson, B.E., Wogan, G.N. and Groopman, J.D. (1994) A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev., 3, 3-10.
51. Wang, L.-Y., Hatch, M., Chen, C.-J. et al. (1996) Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer, 67, 620-625.
52. Harris, C.C. (1994) Solving the viral-chemical puzzle of human liver carcinogenesis (editorial). Cancer Epidemiol. Biomarkers Prev., 3, 1-2.
53. Kensler, T.W., Groopman, J.D. and Wogan, G.N. (1996) Use of carcinogen-DNA and carcinogen-protein adduct biomarkers for cohort selection and as modifiable end points in chemoprevention trials. Principles Chemoprev., 139, 237-248.
54. Jacobson, L.P., Zhang, B.-C., Zhu, Y. et al. (1997) Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol. Biomarkers Prev., 6, 257-265.
55. Kensler, T.W., He, X., Otieno, M. et al. (1998) Oltipraz chemoprevention trial in Qidong, P.R.C.: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol. Biomarkers Prev., 7, 127-134.
56. Wang, J.-S., Shen, X., He, X. et al. (1999) Protective alterations in phase 1 & 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, P.R.C. J. Natl Cancer Inst., in press.
57. Kensler, T.W., Groopman, J.D. and Roebuck, B.D. (1998) Use of aflatoxin adducts as intermediate endpoints to assess the efficacy of chemopreventive interventions in animals and man. Mutat. Res., 402, 165-172.
58. Laken, S.J., Petersen, G.M., Gruber, S.B. et al. (1997) Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nature Genet., 17, 79-83.